News for Atea Pharmaceuticals, Inc. (AVIR)

Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three

Cash Position: Cash, cash equivalents, and marketable securities totaled $425.4 million as of March 31, 2025, down from $454.7 million at the end of 2024.Resea

Atea Pharmaceuticals (AVIR) reports a Q1 2025 net loss of $34.3 million, improving from a $63.2 million loss year-over-year. The company is advancing it

Atea Pharmaceuticals (AVIR) has disclosed positive outcomes from its Phase 2 trial assessing the efficacy and safety of a new daily oral treatment for hepatitis

**media[617238]**

Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea's Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a

**media[611481]**

Atea Pharmaceuticals (AVIR) has announced plans to showcase the comprehensive results from its Phase 2 clinical trial of an innovative hepatitis C treatment dur

Atea Pharmaceuticals (AVIR) has confirmed its engagement with Evercore, a prominent independent investment bank, as part of its ongoing efforts to explore multi

Atea Pharmaceuticals has announced that its Board of Directors has approved a plan to repurchase up to $25 million of the company's common stock. This move demo

Atea Pharmaceuticals, Inc. (AVIR) has announced a significant addition to its Board of Directors by appointing Howard Berman, Ph.D., as a non-voting observer. D

Atea Pharmaceuticals (AVIR) announces a $25 million share repurchase program. Howard H. Berman appointed to the Board of Directors as part of an agreeme

Enters into Agreement with Bradley L. Radoff and Michael Torok BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. ( AVIR) (”œAtea” or

**media[597920]**

Morgan Stanley has revised its price target for Atea Pharmaceuticals (AVIR), reducing it slightly from $6.20 to $6. The financial services firm continues to mai

Atea Pharmaceuticals (AVIR) doses the first patient in its Phase 3 trial C-BEYOND for hepatitis C treatment. The trial evaluates a combination regimen o

Canada-based Venus Concept Inc (VERO) is up over 310 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

**media[582121]**

**media[577694]**